热门资讯> 正文
Invivyd报告PEMGARDA对主要SARS-CoV-2变体KP.3.1.1和LB.1的持续中和作用
2024-09-03 19:29
- New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested
- Center for Disease Control reports KP.3.1.1 is the only major variant increasing in proportionality nationally
- Variants confirmed as susceptible to pemivibart in independent analyses contain key Q493E, s31del, and other mutations that are prominent in circulating SARS-CoV-2 variants
- Data submitted to FDA for anticipated timely updates to PEMGARDA™ Fact Sheet
- Pipeline candidate VYD2311 shows attractive neutralization potency against the same contemporary viruses
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
